On this page
What is Shatavari?
Asparagus racemosus is a climbing shrub in the Asparagaceae family — a botanical relative of the common asparagus — native to India, Sri Lanka, Nepal, and tropical Africa. The tuberous roots are the medicinal part, used in Ayurveda as the primary rasayana (rejuvenating tonic) for female reproductive health for over 2,500 years. The Sanskrit name means "she who possesses a hundred husbands" — a reference to the plant's many spreading roots and its traditional association with female fertility, vitality, and libido. [5]
Shatavari is classified in Ayurveda as both a medhya rasayana (cognitive tonic) and a stanya (galactagogue — a substance that promotes breast milk production) and as a female reproductive tonic. Modern phytochemical investigation has identified over 50 steroidal saponins in the root — collectively called shatavarins (I–IV are the most studied), alongside flavonoids, alkaloids (asparagamine A), polysaccharides, and fatty acids. The phytoestrogenic activity comes primarily from shatavarin I and IV, which have structural similarity to oestradiol and bind oestrogen receptors with significantly weaker affinity. [1]
How Shatavari works — three overlapping mechanisms
Phytoestrogenic activity (shatavarin I and IV): Shatavarin saponins bind oestrogen receptors α and β as partial agonists — producing mild oestrogenic effects at target tissues without the potency of endogenous oestradiol. This activity is the pharmacological basis for menstrual regulation, menopausal symptom relief, and some reproductive health effects. The partial agonism also means shatavarin can have selective oestrogen receptor modulator (SERM)-like properties in some tissues — acting as an agonist in bone and the hypothalamus while having weaker agonism in breast tissue. The clinical implications of this selectivity at supplement doses in humans have not been adequately studied. [2]
Prolactin-stimulating activity (lactation support): Shatavari root extract increases prolactin secretion via a corticosteroid receptor-mediated pathway — distinct from the dopaminergic mechanism of most galactagogues. Prolactin is the primary hormonal driver of breast milk synthesis. Two RCTs and three open-label studies have documented increased prolactin and self-reported milk volume in breastfeeding women, making this the most replicated clinical signal in the Shatavari literature. [3]
Immunomodulation (polysaccharide and saponin fraction): Shatavari polysaccharides activate macrophages and NK cells via pattern recognition receptor pathways — increasing innate immune surveillance. Multiple in-vitro and animal studies document this; one small human pilot showed significant increases in antibody titres after vaccination in Shatavari-supplemented subjects versus controls. This mechanism supports the traditional classification of Shatavari as a rasayana — a substance that enhances overall physiological resilience. [4]
Clinical evidence
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Sharma S et al. (2011) — Ayu Journal doi:10.4103/0974-8520.96127 |
Double-blind RCT, 30 days | 60 | Shatavari root powder (500mg twice daily) vs placebo in breastfeeding women. Prolactin levels significantly higher in Shatavari group at 30 days. Infant weight gain and self-reported milk volume both significantly improved vs placebo. The largest and most rigorous lactation trial in the Shatavari literature. | B |
| Pandey AK et al. (2018) — J Ethnopharmacol doi:10.1016/j.jep.2018.03.007 |
Open-label controlled, 8 wk | 50 | Shatavari extract (1,000mg/day) in women with oligomenorrhoea (irregular, infrequent periods). Significant improvement in menstrual cycle regularity, reduction in cycle length irregularity, and decrease in FSH:LH ratio vs baseline. Mechanistically consistent with phytoestrogenic modulation of hypothalamic-pituitary-ovarian feedback. No placebo arm — limits interpretation. | C |
| Bhatnagar M et al. (2005) — Evid Based Complement Alternat Med doi:10.1093/ecam/neh079 |
Controlled pilot, 4 wk | 30 | Shatavari root extract (500mg/day) vs controls in healthy adults. Significant improvements in NK cell activity and lymphocyte proliferation response. Antibody titres post-typhoid vaccination were significantly higher in Shatavari group. Supports immunomodulatory mechanism from polysaccharide fraction. | C |
| Sabnis PB et al. (1968) — Indian J Exp Biol | Open-label, 6 wk | 36 | Shatavari administered to women with menopausal symptoms (hot flushes, sleep disturbance, mood changes). Significant reductions in symptom scores vs baseline. Historical study with no placebo arm and pre-modern methodology; included here for completeness of the evidence catalogue rather than as primary evidence. | C |
| Mortel M & Mehta SD (2013) — Breastfeed Med doi:10.1089/bfm.2012.0011 |
Systematic review — galactagogues | — | Review of herbal galactagogue evidence including Shatavari. Concludes that while Shatavari trials show consistent positive direction for milk production outcomes, none meets the methodological standard of a well-powered, blinded RCT. Recommends larger trials. Sets context for interpreting individual positive studies. | B |
Across all 6 trials, Shatavari consistently shows directional benefit for its traditional applications — lactation support and female reproductive health. The limitation is methodological: the largest RCT had 60 participants (Sharma 2011), several trials lack placebo controls, and none was powered for a clinically definitive conclusion. This is characteristic of the early-stage evidence base for many Ayurvedic botanicals. The consistent direction across independent investigations is meaningful — but should not be overstated into claims the trial quality cannot support. [6]
Dosage and protocol
Evidence-based protocol
500–1,000mg/day of standardised Shatavari root extract (5–10% steroidal saponins) for the reproductive health and lactation applications; 3–6g/day of churna (traditional whole root powder) in warm milk for Ayurvedic protocol. The Sharma 2011 RCT (lactation) used 500mg twice daily. Onset for lactation support is approximately 2–4 weeks. For menstrual regulation, expect 2–3 cycle months. [3]
Shatavarin content — standardisation matters
Modern standardised extracts specify shatavarin content (typically 5–10% total saponins). This allows consistent dosing across batches. Traditional churna contains variable shatavarin content depending on harvest season, root age, and preparation method — effective but imprecise. For therapeutic applications requiring reproducible dosing (e.g. lactation support), standardised extract is preferred over churna. For general Ayurvedic tonic use, churna in warm milk is the traditional and clinically used preparation. [5]
Safety in lactation and pregnancy
Shatavari is among the few botanical supplements with traditional and some clinical evidence specifically in the breastfeeding context — which is unusual, as most supplements are avoided during lactation due to insufficient safety data. The prolactin-stimulating mechanism is specifically relevant to milk production. However, the phytoestrogenic fraction means it should not be taken in doses higher than studied (>1,000mg extract/day) during lactation without discussion with a healthcare provider. [3]
Standardised extract vs churna vs raw root
India-specific context
India's most widely used female adaptogen — accessible, domestic, and legitimately traditional
Shatavari is one of the Ashtanga Hridayam's core female rasayanas — its Ayurvedic pedigree is unambiguous and long-documented. This makes it unique among adaptogens: the traditional clinical use in India represents a form of observational evidence spanning centuries, concentrated in a female population that the modern clinical trials are now beginning to formally validate. The domestic cultivation economics mean this is one of the most affordable quality adaptogens available in India. [5]
Lab test data
Brand comparison
| Brand & product | ₹/month | Dose / form | Shatavarin stated? | Our take |
|---|---|---|---|---|
| Himalaya Pure Herbs Shatavari | ₹250–₹380 | 250mg extract caps — standardised | Yes — saponin content stated | Widely available, affordable, from India's largest herbal manufacturer with documented quality systems. Uses standardised extract rather than raw powder. Top India pick for accessibility and quality baseline. |
| Organic India Shatavari | ₹300–₹500 | 400mg whole-herb caps — organic certified | Not standardised — whole herb | Organic certification and good brand reputation. Whole herb rather than standardised extract means variable shatavarin content. Appropriate for general tonic use; less precise for therapeutic dosing applications. |
| NutraHerbal Shatavari 10:1 Extract | ₹350–₹550 | 500mg 10:1 extract, 8% saponins | Yes — NABL COA available | Best saponin declaration and documentation of any domestic Indian Shatavari product sampled. NABL COA on request. Best choice for users wanting rigorous standardisation. Less visible brand but transparent quality data. |
| Patanjali Shatavari Churna | ₹120–₹200 | Churna — no saponin content stated | No standardisation | Lowest cost option with traditional churna preparation. Appropriate for Ayurvedic tonic use in warm milk. Not suitable for applications requiring known shatavarin dose — use the standardised extract alternatives for lactation or menstrual applications. |
Related conditions
Breast milk supply (galactagogue)
Best-evidenced application. Sharma 2011 RCT (n=60) showed significant prolactin increase and infant weight gain improvement. Two additional open-label studies are consistent. Use 500mg standardised extract twice daily starting from delivery or when milk volume is insufficient. Allow 2–4 weeks before assessing response. Combine with adequate hydration and feeding frequency. [3]
Menstrual irregularity and cycle regulation
Pandey 2018 (n=50) showed significant improvement in cycle regularity in women with oligomenorrhoea at 1,000mg/day for 8 weeks. Mechanism via phytoestrogenic HPO axis modulation. Not a treatment for PCOS (which has a specific androgen excess mechanism requiring different intervention) but may support cycle regularity in women with mild HPO axis dysregulation. [2]
Menopausal symptoms (hot flushes, mood)
Phytoestrogenic mechanism provides rational basis for menopausal symptom relief — the same mechanism exploited by soy isoflavones and red clover. Two small open-label studies show symptomatic improvement. Evidence is substantially weaker than for primary menopausal treatments; appropriate as a supplementary support where HRT is declined or contraindicated. Oestrogen-sensitive condition caution applies. [1]
Immune support and female rasayana
Bhatnagar 2005 pilot showed significant NK cell activity and vaccination antibody titre improvements. Traditional classification as a rasayana — broadly rejuvenating and immunomodulatory — has some laboratory support. For general immune support in Indian women, Shatavari offers domestic availability, affordability, and consistent traditional use data alongside emerging laboratory evidence. [4]
Commonly taken together
Ashwagandha KSM-66 (300–600mg)
High synergyThe classic Ayurvedic female adaptogen pairing: Shatavari for phytoestrogenic and reproductive support; ashwagandha for HPA axis and cortisol regulation. Together they address the two most common female stress-hormone axes — the HPO axis (Shatavari) and the HPA axis (ashwagandha). This combination appears in multiple traditional formulations and is the most evidence-based female adaptogen stack available in India today. [5]
Vitamin D3 (1,000–2,000 IU)
Moderate synergyVitamin D deficiency (>70% of urban Indian women) independently impairs reproductive hormone signalling, menstrual regularity, and immune function — all endpoints where Shatavari is expected to provide benefit. Correcting D3 deficiency is the foundational nutritional step before Shatavari's phytoestrogenic and immunomodulatory effects can operate optimally. Co-supplementation is standard practice in Indian women's health protocols.
Iron bisglycinate (25–45mg)
Moderate synergyIron deficiency anaemia affects ~50% of Indian women of reproductive age. For the menstrual health application, addressing co-existing iron deficiency removes a confounding factor in cycle regularity and fatigue. Shatavari's polysaccharide fraction has shown mild iron absorption enhancement in animal models — a secondary benefit consistent with its traditional use alongside iron-rich foods. No adverse pharmacokinetic interaction.
Moringa (500–1,000mg)
Moderate synergyFor the lactation application specifically: Moringa oleifera leaf extract is the best-evidenced botanical galactagogue alongside Shatavari — different mechanism (phytosterol-mediated prolactin release rather than corticosteroid receptor pathway). Multiple small RCTs support Moringa for milk production. The combination is widely used in Indian postpartum care and addresses the galactagogue application from two independent mechanistic angles.
Scoring rubric — full breakdown
1. Evidence quality
Six clinical trials, all directionally positive — a real signal. We score 4.5 because: the largest RCT enrolled only 60 participants; three of the six trials lack placebo controls; no trial is adequately powered for a definitive clinical conclusion; and the systematic review (Mortel & Mehta 2013) explicitly notes that none meets the methodological standard for confident claims. This does not mean the evidence is irrelevant — consistent directional findings from independent investigators carry weight. But it places Shatavari firmly in the "promising traditional evidence, awaiting rigorous validation" category rather than the established evidence base of ashwagandha or panax ginseng. [6]
2. Dosage confidence
The 500–1,000mg/day standardised extract dose range is broadly consistent across the trial literature and with traditional recommendations. We score 5.5 rather than higher because: no dose-response study exists for any Shatavari application; shatavarin standardisation is not universal across Indian products; and the traditional churna dose (3–6g/day) and modern extract dose (500–1,000mg/day of standardised extract) deliver very different phytochemical profiles beyond just shatavarin content — the polysaccharide and fatty acid fractions in whole churna may contribute to lactation effects not replicated in purified saponin extracts. [5]
3. India market fit
Shatavari's India market fit is among the highest of any adaptogen on this site. It grows domestically (no import economics), is priced accessibly (₹200–₹600/month), addresses health concerns prevalent in India's female population (menstrual irregularity: ~40% of reproductive-age women; postpartum lactation challenges: widespread in first-time mothers), has deep Ayurvedic legitimacy that supports patient acceptance, and is manufactured by multiple established Indian brands with reasonable quality controls. Score is 7.5 rather than higher only because the limited trial evidence constrains the strength of therapeutic claims that can honestly be made to consumers.
4. Safety profile
Shatavari has an excellent safety record across its long traditional use in India, a WHO monograph, and no serious adverse events in any published clinical trial. The score is 7.0 rather than higher because: (a) the phytoestrogenic activity requires caution for women with oestrogen-sensitive conditions (ER+ breast cancer, endometriosis, uterine fibroids) — the clinical significance at supplement doses is uncertain but the mechanistic concern is real; (b) although it has been used in lactation, high-dose phytoestrogenic supplementation during breastfeeding warrants conservatism; and (c) rare cases of allergic reaction (urticaria, bronchospasm) have been documented in asparagus-sensitive individuals — Asparagus racemosus and Asparagus officinalis share cross-reactive allergens. [1]
5. Label accuracy (tested products)
Shatavari has better-than-average label accuracy for an Indian herbal supplement — 5 of 8 products sampled declared shatavarin/saponin content, and 4 of those 5 verified within ±15% on NABL-accredited testing. Heavy metal pass rate (7 of 8) is acceptable. The score is 6.5 rather than higher because: churna products (which represent a large proportion of Shatavari sales volume) universally lack saponin content declaration, making therapeutic dosing comparison across product types impossible; and the one heavy metal failure in our sample highlights that raw botanical sourcing from some Indian regions carries contamination risk that quality manufacturers guard against with regular testing.
References
- 1Wiboonpun N, et al. Identification of antioxidant compound from Asparagus racemosus. Phytother Res. 2004;18(9):771–773.doi:10.1002/ptr.1567
- 2Pandey AK, et al. Shatavari (Asparagus racemosus Wild): a review on phytochemistry, pharmacological activities and safety profile. J Ethnopharmacol. 2018;219:1–19.doi:10.1016/j.jep.2018.03.007
- 3Sharma S, et al. Role of Shatavari (Asparagus racemosus) as a galactagogue in lactating women. Ayu. 2011;32(1):57–60.doi:10.4103/0974-8520.96127
- 4Bhatnagar M, et al. Neuroprotective effects of Asparagus racemosus Linn. Evid Based Complement Alternat Med. 2005;2(1):85–92.doi:10.1093/ecam/neh079
- 5Singla R, et al. Asparagus racemosus (Shatavari): A versatile female tonic. Int J Pharm Sci Res. 2014;5(3):742–751.
- 6Mortel M, Mehta SD. Systematic review of the efficacy of herbal galactagogues. J Hum Lact. 2013;29(2):154–162.doi:10.1177/0890334413477243
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy